SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Laboratory Services, Illumina's CLIA-certified laboratory, is providing clinical sequencing and ...

Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc.

Tuberculosis (TB) is the world’s leading cause of death from a single infectious agent, affecting more than 10 million people ...

Tempus AI's diagnostics arm is surging in 2025 as precision oncology testing, MRD adoption, AI-driven genomic tools and the Ambry Genetics acquisition expand capabilities.

TEM advances precision oncology as studies validate IPS, PurIST and xF+ diagnostics, highlighting stronger guidance for cancer therapy and biomarker detection.

The viral Rosie story credited AI with designing a custom cancer vaccine. The scientists who actually made it say the credit ...

Sjögren-Larsson syndrome (SLS) constitutes a rare genetic disorder manifesting as a complex neurocutaneous condition ...

Current Landscape of Life Sciences The life sciences sector, encompassing pharmaceuticals, biotechnology, and medical devices ...

Rare diseases, defined in the U.S. as conditions affecting fewer than 200,000 people, can take years, if not decades, to ...

MSD is paying $20 million upfront to activate an alliance with Flagship Pioneering's Quotient Therapeutics that will focus on ...